University Research Co. awarded funds to fight TB

University Research Co., LLC, has been awarded $225 million for a five year project to fight tuberculosis in countries most affected by the highly contagious and deadly bacterial infection.

The funds are part of the TB CARE II project awarded to the Maryland-based company by the U.S. Agency for International Development. The TB CARE II program, officials said, will be one of the primary global mechanisms for fighting tuberculosis.

URC president Barbara Turner said she is excited about the funding.

“URC is thrilled to announce our participation in this new collaboration with USAID as it affords an opportunity to apply URC's 45 years of lessons learned in improving health systems to the international Stop TB efforts,” Turner said. “TB CARE II builds on URC's long commitment to fighting tuberculosis.”

Turner said URC has worked on numerous TB control projects with support from USAID, the U.S. Centers for Disease Control and Prevention and the Southern African Development Community. Since the 1990s, URC has assisted in developing TB control systems in more than a dozen countries in Africa, Asia, Latin America and Europe, according to Turner.

The project will be led by Dr. Refiloe Matji, an international expert on TB control. Matji has spent 15 years developing national TB prevention programs and has served as a program manager for the National TB Control Program in South Africa.

“This project is timely and will go a long way towards fighting this deadly disease,” Matji said. “I’m glad to be part of this tremendous effort, with the support of USAID, which I believe will serve a great need in many countries in Africa, Asia, Latin America and Europe.”

Organizations in this Story

U.S. Agency for International Development

Want to get notified whenever we write about U.S. Agency for International Development ?
Next time we write about U.S. Agency for International Development, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.